Phenprocoumon

Phenprocoumon
Clinical data

Trade names	Marcoumar, Marcumar, Falithrom
AHFS/Drugs.com	International Drug Names
MedlinePlus	a699003
ATC code	B01AA04 (WHO)
Legal status
Legal status	℞ (Prescription only)
Pharmacokinetic data
Protein binding	99%
Metabolism	hepatic to inactive metabolites
Biological half-life	5 to 6 days
Identifiers
IUPAC name (RS)-4-hydroxy-3-(1-phenylpropyl)-2H-chromen-2-one
CAS Number	435-97-2^Y
PubChem (CID)	9908
IUPHAR/BPS	6839
DrugBank	DB00946^Y
ChemSpider	10441592^Y
UNII	Q08SIO485D^Y
KEGG	D05457^Y
ChEBI	CHEBI:50438^Y
ChEMBL	CHEMBL1465^Y
ECHA InfoCard	100.006.464
Chemical and physical data
Formula	C₁₈H₁₆O₃
Molar mass	280.318 g/mol
3D model (Jmol)	Interactive image
SMILES OC=1c3ccccc3OC(=O)C=1C(CC)c2ccccc2
InChI InChI=1S/C18H16O3/c1-2-13(12-8-4-3-5-9-12)16-17(19)14-10-6-7-11-15(14)21-18(16)20/h3-11,13,19H,2H2,1H3^Y Key:DQDAYGNAKTZFIW-UHFFFAOYSA-N^Y
(verify)

Phenprocoumon (marketed under the brand names Marcoumar, Marcumar and Falithrom) is a long-acting oral anticoagulant drug, a derivative of coumarin. It is a vitamin K antagonist that inhibits coagulation by blocking synthesis of coagulation factors II, VII, IX and X. It is used for the prophylaxis and treatment of thromboembolic disorders (thrombosis/pulmonary embolism). It is the standard coumarin used in Germany.

Phenprocoumon is a 4-hydroxycoumarin and inhibits vitamin K epoxide reductase.^[1]

References

↑ Phenprocoumon at PharmGKB

External links

DDB 29943

Antithrombotics (thrombolytics, anticoagulants and antiplatelet drugs) (B01)

Antiplatelet drugs

Glycoprotein IIb/IIIa inhibitors	Abciximab Eptifibatide Orbofiban Roxifiban Sibrafiban^§ Tirofiban

ADP receptor/P2Y₁₂ inhibitors	Thienopyridines Clopidogrel Prasugrel Ticlopidine Nucleotide/nucleoside analogs Cangrelor Elinogrel Ticagrelor

Prostaglandin analogue (PGI2)	Beraprost Iloprost Prostacyclin Treprostinil

COX inhibitors	Acetylsalicylic acid/Aspirin^# Aloxiprin Carbasalate calcium Indobufen Triflusal

Thromboxane inhibitors	Thromboxane synthase inhibitors Dipyridamole (+ aspirin) Picotamide Terbogrel Receptor antagonists Terbogrel Terutroban^§

Phosphodiesterase inhibitors	Cilostazol Dipyridamole Triflusal

Other	Cloricromen Ditazole Vorapaxar

Anticoagulants

Vitamin K antagonists
(inhibit II, VII, IX, X)

Factor Xa inhibitors
(with some II inhibition)

Heparin group/ glycosaminoglycans/ (bind antithrombin)	Low molecular weight heparin Bemiparin Certoparin Dalteparin Enoxaparin Nadroparin Parnaparin Reviparin Tinzaparin^‡ Oligosaccharides Fondaparinux Idraparinux^§ Heparinoids Danaparoid Dermatan sulfate Sulodexide

Direct Xa inhibitors ("xabans")	Apixaban Betrixaban^† Darexaban^§ Edoxaban Otamixaban^§ Rivaroxaban

Direct thrombin (IIa) inhibitors

Other

Thrombolytic drugs/
fibrinolytics

Non-medicinal

^#WHO-EM
^‡Withdrawn from market
Clinical trials:
- ^†Phase III
- ^§Never to phase III

Types of coumarins

Aglycones

O-Methylated	Fraxetin Herniarin (7-O-Methylumbelliferone) Osthol Scopoletin (6-Methoxyumbelliferone)

glycosides

Aesculin (Esculetin 6-O-glucoside)
Fraxin (Fraxetin glucoside)
Skimmin (Umbelliferone 7-O-glucoside)
Scopolin
Umbelliferone 7-apiosylglucoside

derivatives

Furanocoumarins

Aglycones

Angelicin
Marmesin
Psoralen
Vaginol
Xanthotoxol (8-Hydroxypsoralen)

O-Methylated	Bergapten (5-methoxypsoralen) Isopimpinellin (5,8-Dimethoxypsoralene) Methoxsalen (8-Methoxypsoralen) Trioxsalen (2,5,9-Trimethylpsoralen)

Furanocoumarin glycosides

Apterin (vaginol glucoside)

Meroterpene furanocoumarin ether

Oligomers

Dicoumarol

Synthetic

This article is issued from Wikipedia - version of the 4/2/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.